PMID- 27352191
OWN - NLM
STAT- MEDLINE
DCOM- 20170907
LR  - 20200828
IS  - 1536-3678 (Electronic)
IS  - 1077-4114 (Print)
IS  - 1077-4114 (Linking)
VI  - 38
IP  - 5
DP  - 2016 Jul
TI  - Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active 
      Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and 
      Asparaginase Intolerance.
PG  - 345-9
LID - 10.1097/MPH.0000000000000560 [doi]
AB  - BACKGROUND: Children with relapsed acute lymphoblastic leukemia (ALL) typically 
      receive vincristine-prednisone-L-asparaginase-doxorubicin reinduction 
      chemotherapy similar to contemporary induction regimens. However, up to 20% of 
      patients are unable to receive vincristine-prednisone-L-asparaginase-doxorubicin 
      secondary to asparaginase intolerance. We report our experience with a promising 
      reinduction regimen for children with relapsed ALL who are unable to receive 
      asparaginase. PATIENTS AND METHODS: This is a single institution, retrospective 
      review of the safety and activity of bortezomib, dexamethasone, mitoxantrone, and 
      vinorelbine (BDMV) in patients with relapsed ALL. Complete remission and adverse 
      events after reinduction were study endpoints. Patients treated with BDMV between 
      2012 and 2015 were identified. Response and adverse events (AEs) were assessed by 
      review of medical records. Standard response criteria were used and AEs were 
      graded based on NCI CTCAEv4.0. RESULTS: Seven of 10 patients achieved complete 
      remission after 1 cycle of BDMV, with 4 achieving minimal residual disease 
      negativity. The most common >/=grade 3 nonhematological toxicities were infection 
      (91%), gastrointestinal (45%), metabolic (45%), and cardiovascular (9%). 
      CONCLUSIONS: BDMV is an active reinduction regimen for children with relapsed ALL 
      who cannot receive asparaginase. The toxicity profile is as expected for this 
      patient population. Further prospective clinical trials are warranted to evaluate 
      the safety and efficacy of BDMV.
FAU - Yeo, Kee K
AU  - Yeo KK
AD  - *Children's Center for Cancer and Blood Diseases, Division of Hematology, 
      Oncology and Blood & Marrow Transplantation, Children's Hospital Los 
      AngelesdaggerNorris Comprehensive Cancer Center, Keck School of Medicine, University 
      of Southern California, Los Angeles, CA.
FAU - Gaynon, Paul S
AU  - Gaynon PS
FAU - Fu, Cecilia H
AU  - Fu CH
FAU - Wayne, Alan S
AU  - Wayne AS
FAU - Sun, Weili
AU  - Sun W
LA  - eng
GR  - P30 CA014089/CA/NCI NIH HHS/United States
PT  - Journal Article
PL  - United States
TA  - J Pediatr Hematol Oncol
JT  - Journal of pediatric hematology/oncology
JID - 9505928
RN  - 5V9KLZ54CY (Vinblastine)
RN  - 69G8BD63PP (Bortezomib)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - BZ114NVM5P (Mitoxantrone)
RN  - EC 3.5.1.1 (Asparaginase)
RN  - Q6C979R91Y (Vinorelbine)
SB  - IM
MH  - Adolescent
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Asparaginase/adverse effects
MH  - Bortezomib/administration & dosage
MH  - Child
MH  - Child, Preschool
MH  - Dexamethasone/administration & dosage
MH  - Female
MH  - Humans
MH  - Infant
MH  - Male
MH  - Mitoxantrone/administration & dosage
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications/*drug therapy
MH  - Recurrence
MH  - Remission Induction/*methods
MH  - Retrospective Studies
MH  - Vinblastine/administration & dosage/analogs & derivatives
MH  - Vinorelbine
MH  - Young Adult
PMC - PMC7451259
MID - NIHMS1619884
COIS- The authors declare no conflict of interest.
EDAT- 2016/06/29 06:00
MHDA- 2017/09/08 06:00
PMCR- 2020/08/27
CRDT- 2016/06/29 06:00
PHST- 2016/06/29 06:00 [entrez]
PHST- 2016/06/29 06:00 [pubmed]
PHST- 2017/09/08 06:00 [medline]
PHST- 2020/08/27 00:00 [pmc-release]
AID - 00043426-201607000-00004 [pii]
AID - 10.1097/MPH.0000000000000560 [doi]
PST - ppublish
SO  - J Pediatr Hematol Oncol. 2016 Jul;38(5):345-9. doi: 10.1097/MPH.0000000000000560.